title: CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER²⁺ Breast Cancer.
abstract: CDK4/6 inhibitors have received approval for treating hormone-positive breast tumors, but whether other aggressive cancers respond to these molecules is not yet clear. In this issue of Cancer Cell, Goel et al. (2016) report an unexpected activity of CDK4/6 inhibitors in reducing mTOR function and re-sensitizing HER2-positive cancers to EGFR/HER2 blockade.
authors.affiliation: Cell Division and Cancer Group, Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández Almagro 3, E-28029 Madrid, Spain. Electronic address: malumbres@cnio.es.
authors.forename: Marcos
authors.initials: M
authors.lastname: Malumbres
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy*; D051358:Cyclin-Dependent Kinase 4 / Q000037:antagonists & inhibitors*; D051361:Cyclin-Dependent Kinase 6 / Q000037:antagonists & inhibitors*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*
chemical_list: D051358:Cyclin-Dependent Kinase 4; D051361:Cyclin-Dependent Kinase 6; D047428:Protein Kinase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases